# INTERVIEW: OptiBiotix Health Plc – An exciting time for investors

- Link: https://www.directorstalkinterviews.com/interview-optibiotix-health-plc-exciting-time-investors/412727094
- Published: 2017-04-11T15:12:43+01:00
- Author: Giles Arbor

**OptiBiotix Health Plc** (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about
the listing of **SkinBiotheraputics** (LON:SBTX). Stephen explains the rationale
behind the launch, what this could mean for OptiBiotix investors, the timing involved
and how this all fits into the company strategy.

OptiBiotix Health plc has established a pipeline of microbiome modulators that can
impact on lipid and cholesterol management, energy harvest and appetite suppression.
The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic
® platform technologies designed to identify metabolic pathways and compounds that
impact on human physiology and bring potential health benefits. These platforms 
are applicable across a wider range of other human diseases.

SkinBioTherapeutics is a life science company focused on skin health. The Company’s
proprietary platform technology, SkinBiotix™, is based upon discoveries made by 
CEO Dr. Catherine O’Neill and Professor Andrew McBain. The company is targeting 
three specific markets; cosmetics, infection control and eczema. In each of these
areas the Company intends to exemplify its technology in human studies.  The most
advanced programme is focused on creating an ingredient for the cosmetics industry
to treat sensitive skin. The business strategy is to outlicense its programmes at
proof of concept.

Share on: